Leptomeningeal metastasis

Cancer Investigation

Volumn 23, Issue 2, 2005, Pages 145-154

  DeAngelis, Lisa M ^a   Boutros, Dina ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chemotherapy; Intrathecal chemotherapy; Leptomeningeal metastasis; Radiotherapy

Indexed keywords

CORTICOSTEROID; CYTARABINE; DEXAMETHASONE; FOLINIC ACID; METHOTREXATE; THIOTEPA;

ARACHNOIDITIS; ARTICLE; ATAXIA; BLEEDING; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID FLOW; CHEMOTHERAPY INDUCED EMESIS; CLINICAL FEATURE; CLINICAL TRIAL; CRANIAL NERVE; CYTOLOGY; DEMENTIA; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FEVER; DRUG TOLERABILITY; EARLY DIAGNOSIS; HEADACHE; HEMATOPOIETIC SYSTEM TUMOR; HUMAN; LABORATORY TEST; LEPTOMENINGEAL METASTASIS; LEUKEMIA; LUMBAR PUNCTURE; LYMPHOMA; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NERVE FIBER; NEUROIMAGING; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADICULOPATHY; SIDE EFFECT; TREATMENT WITHDRAWAL;

EID: 16244393755     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1081/CNV-50458     Document Type: Article

References (65)

1. Cantillo, R.; Jain, J.; Singhakowinta, A.; Vaitkevicius, V. Blindness as initial manifestation of meningeal carcinomatosis in breast cancer. Cancer 1979, 44, 755-757.
2. Eberth, C. Zur entwick pung des ephlheliomas (cholesteatomas) der pia and der lung. Virchow S. Arch. 1870, 49, 51-63.
3. Dufour, H. Meningite sarcomateuse diffuse avec envahissement de las melle et das racines: cytologie positive et speciale du liquide cephalorachidien. Rev. Neurol. 1904, 12, 104-106.
4. Beerman, W. Meningeal carcinomatosis. JAMA 1912, 58, 1437-1439.
5. Posner, J. Neurologic Complications of Cancer, F.A. Davis Co.: Philadelphia, Pennsylvania, 1995; 482 pp.
6. Bendell, J.C.; Domchek, S.M.; Burstein, H.J.; Harris, L.; Younger, J.; Kuter, I.; Bunnell, C.; Rue, M.; Gelman, R.; Winer, E. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003, 97, 2972-2977.
7. Rosen, S.; Aisner, J.; Makuch, R.W.; Matthews, M.J.; Ihde, D.C.; Whitacre, M.; Glatstein, E.J.; Wiernik, P.H.; Lichter, A.S.; Bunn, P.A., Jr. Carcinomatous leptomeningitis in small cell lung cancer: a clinicopathologic review of the National Cancer Institute experience. Am. J. Med. 1987, 61, 45-53.
8. Kesari, S.; Batchelor, T.T. Leptomeningeal metastases. Neurol. Clin. 2003, 21, 25-66.
9. Aroney, R.S.; Dalley, D.N.; Chan, W.K.; Bell, D.R.; Levi, J.A. Meningeal carcinomatosis in small cell carcinoma of the lung. Am. J. Med. 1981, 71, 26-32.
10. Freilich, R.J.; Seidman, A.D.; DeAngelis, L.M. Central nervous system progression of metastatic breast cancer in patients treated with paclitaxel. Cancer 1995, 76, 232-236.
11. van der Ree, T.C.; Dippel, D.W.; Avezaat, C.J.; Sillevis Smitt, P.A.; Vecht, C.J.; van den Bent, M.J. Leptomeningeal metastasis after surgical resection of brain metastases. J. Neurol. Neurosurg. Psychiatry 1999, 66 (2), 225-227.
12. Olson, M.; Chernik, N.; Posner, J. Infiltration of the leptomeninges by systemic cancer: a clinical and pathologic study. Arch. Neurol. 1994, 30, 122-137.
13. Wasserstrom, W.; Glass, J.; Posner, J. Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 1982, 49, 759-772.
14. Kaplan, J.; DeSouza, T.; Farkash, A.; Shafran, B.; Pack, D.; Rehman, F.; Fuks, J.; Portenoy, R. Leptomeningeal metastases: comparison of clinical features and laboratory data of solid tumors, lymphomas and leukemias. J. Neuro.-Oncol. 1990, 92, 25-29.
15. Balm, M.; Hammack, J. Leptomeningeal carcinomatosis. Arch. Neurol. 1996, 53, 626-632.
16. Hansen, K.; Gjerris, F.; Sorensen, P.S. Absence of hydrocephalus in spite of impaired cerebrospinal fluid absorption and severe intracranial hypertension. Acta Neurochir. (Wien) 1987, 86, 93-97.
17. Madow, L.; Alpers, B.; Akerley, W. Encephalitic form of metastatic carcinoma. Arch. Neurol. Psychiat. 1951, 65, 161-173.
18. Chamberlain, M.; Sandy, A.; Press, G. Leptomeningeal metastasis. A comparison of GAD-enhanced MR and contrast enhanced CT of the brain. Neurology 1990, 40, 435-438.
19. Freilich, R.J.; Krol, G.; DeAngelis, L.M. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann. Neurol. 1995, 38, 51-57.
20. Collie, D.A.; Brush, J.P.; Lammie, G.A.; Grant, R.; Kunkler, I.; Leonard, R.; Gregor, A.; Sellar, R.J. Imaging features of leptomeningeal metastases. Clin. Radiol. 1999, 54, 765-771.
21. Abrey, L.E.; Rosenblum, M.K.; DeAngelis, L.M. Sarcoidosis of the cauda equina mimicking leptomeningeal malignancy. J. Neurooncol. 1998, 39 (3), 261-265.
22. Lo, Y.L.; Wong, M.C.; Chan, L.L.; Lim, P.A. Sulcal abnormalities on brain magnetic resonance imaging in the Guillain-Barre syndrome. J. Neurol. Neurosurg. Psychiatry 2002, 73 (1), 92-93.
23. Lin, W.C.; Lirng, J.F.; Fuh, J.L.; Wang, S.J.; Chang, F.C.; Ho, C.F.; Teng, M.M.; Chang, C.Y. MR findings of spontaneous intracranial hypotension. Acta Radiol. 2002, 43 (3), 249-255.
24. Spelle, L.; Boulin, A.; Tainturier, C.; Visot, A.; Graveleau, P.; Pierot, L. Neuroimaging features of spontaneous intracranial hypotension. Neuroradiology 2001, 43 (8), 622-627.
25. 111Indium-DTPA cerebrospinal fluid (CSF) studies in leptomeningeal metastases (LM) predict intrathecal methotrexate (MTX) distribution and outcome in patients with LM. Neurology 1998, 50, 438-443.
26. Glantz, M.J.; Hall, W.A.; Cole, B.F.; Chozick, B.S.; Shannon, C.M.; Wahlberg, L.; Akerley, W.; Marin, L.; Choy, H. Diagnosis, management and survival of patients with leptomeningeal cancer based on cerebrospinal fluid flow studies. Cancer 1995, 75, 2919-2931.
27. Adachi, N. Beta-2-microglobulin levels in the cerebrospinal fluid: their value as a disease marker. A review of the recent literature. Eur. Neurol. 1991, 31, 181-185.
28. DeAngelis, L. Current diagnosis and treatment of leptomeningeal metastasis. J. Neuro.-Oncol. 1998, 38, 245-252.
29. Twinjstra, A.; Ongerboer de Visser, B.W.; van Zanten, A.P.; Hart, W.J. Serial lumbar and ventricular cerebrospinal fluid biochemical marker measurements in patients with leptomeningeal metastases from solid and hematological tumors. J. Neurooncol. 1989, 7 (1), 57-63.
30. Glass, J.; Melamed, M.; Chernik, N.; Posner, J. Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology. Neurology 1979, 29, 1369-1375.
31. Rogers, L.R.; Duchesneau, P.M.; Nunex, C.; Fishlecler, A.J.; Weick, J.K.; Bauer, L.J.; Boyett, J.M. Comparison of cisternal and lumbar CSF examination in leptomeningeal metastasis. Neurology 1992, 42, 1239-1241.
32. Gleissner, B.; Siehl, J.; Korfel, A.; Reinhardt, R.; Thiel, E. CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes. Neurology 2002, 58 (3), 390-396.
33. Rhodes, C.H.; Glantz, M.J.; Glantz, L.; Lekos, A.; Sorenson, G.D.; Honsinger, C.; Levy, N.B. A comparison of polymerase chain reaction examination of cerebrospinal fluid and conventional cytology in the diagnosis of lymphomatous meningitis. Cancer 1996, 77 (3), 543-548.
34. van Oostenbrugge, R.J.; Hopman, A.H.N.; Arends, J.W.; Ramaekers, F.C.; Twijnstra, A. The value of interphase cytogenetics in cytology for the diagnosis of leptomeningeal metastases. Neurology 1998, 51, 906-908.
35. Storch-Hagenlocher, B.; Haas, J.; Vogt-Schaden, M.E.; Bentz, M.; Hoffman, L.A.; Biessmann, A.; Wildemann, B. Molecular analysis of the CDR3 diagnostic tool in lymphomatous meningitis. Ann. Neurol. 2000, 47 (2), 2111-2117.
36. Kleinschmidt-DeMasters, B.K.; Evans, L.C.; Bitter, M.A.; Shroyer, A.L.; Shroyer, K.R. Part II. Telomerase expression in cerebrospinal fluid specimens as an adjunct to cytologic diagnosis. J. Neurol. Sci. 1998, 161 (2), 124-134.
37. DeAngelis, L.M.; Posner, J.B. Telomerase activity in brain and leptomeningeal metastases. J. Neurol. Sci. 1998, 161, 114.
38. Stockhammer, G.; Poewe, W.; Burgstaller, S.; Deisenhammer, F.; Muigg, A.; Kiechl, S.; Schmutzhard, E.; Maier, H.; Felber, S.; Schumacher, P.; Gunsilius, E.; Gastl, G. Vascular endothelial growth factor in CSF. Neurology 2000, 45, 1670-1676.
39. Gray, J.; Wallner, K. Reversal of cranial nerve dysfunction with RT in adults with lymphoma. Int. J. Radial. Oncol. Biol. Phys. 1990, 19, 439-444.
40. Chamberlain, M. New approaches to current treatment of leptomeningeal metastases. Curr. Opin. Neurol. 1994, 7, 492-500.
41. Shapiro, W.; Young, D.; Mehta, B. Methotrexate distribution in CSF after intravenous, ventricular and lumbar injections. N. Engl. J. Med. 1975, 293, 161-166.
42. Blasberg, R. Methotrexate, cytosine arabinoside, and BCNU concentration in brain after ventriculocisternal perfusion. Cancer Treat. Rep. 1977, 61, 625-631.
43. Grossman, S.; Reinhard, C.; Loats, H. The intracerebral penetration of intraventricularly administered methotrexate: a quantitative autoradiographic study. J. Neuro.-Oncol. 1989, 7, 319-328.
44. Larson, S.; Schall, G.; DiChiro, G. The influence of previous lumbar puncture and pneumoencephalography on the incidence of unsuccessful radioisotope cisternography. J. Nucl. Med. 1971, 12, 555-557.
45. 111Indium-DTPA CSF flow studies. Neurology 1991, 41, 1765-1769.
46. Moser, A.M.; Adamson, P.C.; Gillespie, A.J.; Poplack, D.G.; Balis, F.M. Intraventricular concentration times time (C x T) methotrexate and cytarabine for patients with recurrent meningeal leukemia and lymphoma. Cancer 1999, 85, 511-516.
47. Grossman, S.; Finkelstein, D.; Ruckdeschelj, C.; Trump, D.; Moynihan, T.; Ettinger, L. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously unhealed neoplastic meningitis. J. Clin. Oncol. 1993, 11, 561-569.
48. Jaeckle, K.A.; Batchelor, T.; O'Day, S.J.; Phuphanich, S.; New, P.; Lesser, G.; Cohn, A.; Gilbert, M.; Aiken, R.; Heros, D.; Rogers, L.; Wong, E.; Fulton, D.; Gutheil, J.C.; Baidas, S.; Kennedy, J.M.; Mason, W.; Moots, P.; Russell, C.; Swinnen, L.J.; Howell, S.B. An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis. J. Neurooncol. 2002, 57, 231-239.
49. Glantz, M.J.; Jaeckle, K.A.; Chamberlain, M.C.; Phuphanich, S.; Recht, L.; Swinnen, L.J.; Maria, B.; LaFollette, S.; Schumann, G.B.; Cole, B.F.; Howell, S.B. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin. Cancer Res. 1999, 5 (11), 3394-3402.
50. Cole, B.F.; Glantz, M.J.; Jaeckle, K.A.; Chamberlain, M.C.; Mackowiak, J.I. Quality-of-life adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis. Cancer 2003, 97 (12), 3053-3060.
51. Chamberlain, M.; Khatibi, S.; Kim, J.; Howell, S.; Chatelut, E.; Kim, S. Treatment of leptomeningeal metastasis with intraventricular administration of depot cytarabine (DTA 101). A phase I study. Arch. Neurol. 1993, 50, 261-264.
52. Chamberlain, M.C.; Kormanik, P.A.; Barba, D. Complications associated with Intraventricular Chemotherapy in Patients with Leptomeningeal Metastases. J. Neurosurg. 1997, 87 (5), 694-699.
53. Sandberg, D.I.; Bilsky, M.H.; Souweidane, M.M.; Bzdil, J.; Gutin, P.H. Ommaya reservoirs for the treatment of leptomeningeal metastases. Neurosurgery 2000, 47, 49-55.
54. Glantz, M.J.; Cole, B.F.; Recht, L.; Akerley, W.; Mills, P.; Saris, S.; Hochberg, F.; Calabresi, P.; Egorin, M.J. High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? J. Clin. Oncol. 1998, 16, 1561-1567.
55. Tetef, M.L.; Margolin, K.A.; Doroshow, J.H.; Akman, S.; Leong, L.A.; Morgan, R.J., Jr.; Raschko, J.W.; Slatkin, N.; Somlo, G.; Longmate, J.A.; Carroll, M.I.; Newman, E.M. Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. Cancer Chemother. Pharmacol. 2000, 46 (1), 19-26.
56. Morra, E.; Lazzarino, M.; Brusamolino, E.; Pagnucco, G.; Castagnola, C.; Bernasconi, P.; Orlandi, E.; Corso, A.; Santagostino, A.; Bernasconi, C. The role of systemic high-dose cytarabine in the treatment of central nervous system leukemia. Clinical results in 46 patients. Cancer 1993, 72 (2), 439-445.
57. Berg, S.L.; Chamberlain, M.C. Systemic chemotherapy, intrathecal chemotherapy, and symptom management in the treatment of leptomeningeal metastasis. Curr. Oncol. Rep. 2003, 5 (1), 29-40.
58. Grant, R.; Naylor, B.; Greenberg, H.; Junck, L. Clinical outcome in aggressively treated meningeal carcinomatosis. Arch. Neurol. 1994, 51, 457-461.
59. Siegal, T.; Lossos, A.; Pfeffer, M. Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined-modality therapy. Neurology 1994, 44, 1463-1469.
60. Mencel, P.; DeAngelis, L.; Motzer, R. Hormonal ablation as effective therapy for carcinomatosis meningitis from prostate cancer. Cancer 1994, 73, 1892-1894.
61. Boogerd, W.; Dorresteijn, L.D.; van Der Sandle, J.J.; de Gast, G.C.; Bruning, P.F. Response of leptomeningeal metastases from breast cancer to hormonal therapy. Neurology 1999, 55 (1), 117-119.
62. Herrlinger, U.; Schmidberger, H.; Buchhol, R.; Wehrmann, M.; Vallera, D.A.; Schabet, M. Intrathecal therapy of leptomeningeal CEM T-cell lymphoma in nude rats with anti-CD7 ricin toxin A chain immunotoxin. J. Neurooncol. 1998, 40 (1), 1-9.
63. Kochi, M.; Kuratsu, J.; Mihara, Y.; Takaki, S.; Seto, H.; Uemura, S.; Ushio, Y. Ventriculolumbar perfusion of 3-[(4-amino-2-methyl-5-pyrimidinyl) methyl]-1-(2-chloroethyl)-1-nitrosourea hydrochloride. Neurosurgery 1993, 33, 817-823.
64. Chamberlain, M.C. A phase II trial of intra-cerebrospinal fluid alpha-interferon in the treatment of neoplastic meningitis. Cancer 2002, 94, 2675-2680.
65. 2. Cancer 2001, 91, 1809-1813.